Quote | Evaxion Biotech A/S (NASDAQ:EVAX)
Last: | $4.13 |
---|---|
Change Percent: | -0.97% |
Open: | $4.18 |
Close: | $4.13 |
High: | $4.18 |
Low: | $4.05 |
Volume: | 10,156 |
Last Trade Date Time: | 04/24/2024 03:00:00 am |
News | Evaxion Biotech A/S (NASDAQ:EVAX)
Significant Phase 2 clinical trial progress obtained with first patient finalizing EVX-01 vaccine dosing Favorable safety profile confirmed Trial on track for one-year clinical efficacy readout in Q3 2024 COPENHAGEN, Denmark, April 17, 2024 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S ...
2024-04-02 14:10:02 ET Evaxion Biotech A/S (EVAX) Q4 2023 Results Conference Call April 02, 2024 09:00 AM ET Company Participants Christian Kanstrup - Chief Executive Officer Birgitte Rono - Chief Scientific Officer Jesper Nissen - Chief Operating Officer and Chi...
Message Board Posts | Evaxion Biotech A/S (NASDAQ:EVAX)
Subject | By | Source | When |
---|---|---|---|
Back inside the bollinger. Watching to reload. | BooDog | investorshub | 04/18/2023 2:23:15 PM |
$EVAX 1.49. 50 DMA support @ 1.33. | BooDog | investorshub | 04/17/2023 2:03:07 PM |
Took a few more here. Like how | BooDog | investorshub | 04/13/2023 4:42:51 PM |
$EVAX......................................https://stockcharts.com/h-sc/ui?s=$EVAX | glenn1919 | investorshub | 02/08/2023 1:43:58 PM |
1.64 Some may think this is a discount. | BooDog | investorshub | 01/04/2023 1:31:56 PM |
News, Short Squeeze, Breakout and More Instantly...
Evaxion Biotech A/S Company Name:
EVAX Stock Symbol:
NASDAQ Market:
Significant Phase 2 clinical trial progress obtained with first patient finalizing EVX-01 vaccine dosing Favorable safety profile confirmed Trial on track for one-year clinical efficacy readout in Q3 2024 COPENHAGEN, Denmark, April 17, 2024 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S ...
Evaxion and its collaborator tested Evaxion-designed vaccine antigens against Staphylococcus aureus in a clinically relevant animal model of surgical site infections The vaccine antigens significantly protected large, non-rodent animals against surgical site infections, indicating promisi...
Precision vaccine project initiated with the ambition to obtain Preclinical Proof-of-Concept by H2 2024. The novel concept entails AI-identification of a new class of cancer vaccine targets, named endogenous retroviruses (ERVs), broadening the potential of cancer vaccines. Successful completi...